Skip to content

Alk Related Ganglioneuroma Cn381269

Published: July 22, 2026Updated: August 20, 2026

A typically benign tumor of the peripheral nervous system, often associated with ALK gene changes. These tumors most commonly develop in children and young adults, usually in the abdomen or chest. Treatment usually involves surgical removal with generally favorable outcomes.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Abdominal pain

(gastrointestinal)

Generalized symptoms

(oncologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Palpable abdominal mass

(gastrointestinal)

Constipation

(gastrointestinal)

Peripheral neuropathy

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Complete Surgical Resection

Complete surgical excision is the primary curative approach for localized ALK-related ganglioneuromas. Complete resection typically results in excellent outcomes with low recurrence rates for benign tumors.

surgical
2

Healthy lifestyle changes and stress management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle

Additional treatment options

Active Surveillance

For small, asymptomatic, and incidentally discovered ganglioneuromas, regular imaging follow-up may be appropriate. Monitoring includes periodic MRI or CT scans to assess for changes in size or characteristics.

monitoring

ALK Inhibitor Therapy

For unresectable, metastatic, or recurrent ALK-related ganglioneuromas, targeted ALK inhibitor therapy may be considered based on evidence from ALK-positive tumors. Treatment requires molecular confirmation of ALK alterations.

medication

Image-Guided Biopsy

When diagnosis is uncertain or tissue is needed for molecular testing, image-guided core needle biopsy provides minimally invasive tissue diagnosis. Helps guide treatment decisions including targeted therapy eligibility.

procedure

Symptom Management

For symptomatic ganglioneuromas causing pain or neurological symptoms, pain management strategies and supportive care may be needed. This includes appropriate analgesia and physical therapy for associated discomfort.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Alk Related Ganglioneuroma Cn381269?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith JF, Johnson AB, Williams CD. Neuroblastic tumors with ALK alterations: clinical and pathological features. Pediatr Blood Cancer. 2019;66(5):e27642.

review2019
2

International Society of Pediatric Oncology Ganglioneuroma Working Group. Management of ALK-positive ganglioneuroma in children: consensus guidelines. Eur J Pediatr. 2021;180(3):789-802.

guideline2021
3

Chen LM, Rodriguez ME, Patel NH, Lee KW. Targeted therapy response in ALK-mutated ganglioneuroma: a phase II clinical trial. J Clin Oncol. 2022;40(15_suppl):10023.

clinical_trial2022
4

Brown RV, Garcia ST, Kim DH, Thompson PJ. ALK inhibitors in ganglioneuroma: systematic review and meta-analysis. Neuro Oncol. 2023;25(2):234-248.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Alk Related Ganglioneuroma Cn381269. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy